Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You amaze me. Every time you post you reveal your lack of intelligence. A prediction based on Fibonacci retracement is NOT A FACT. The concept of Fibonacci numbers is a mathematical theory that has been applied to certain observed natural phenomena. A subsequent attempt has been made to apply it to social phenomena, economics, and finance, with far more limited results in predictive value. So, first you offered only a highly suspect justification for your prediction, not a fact. Secondly, Fibinacci numbers are only approximate in nature and have far less than 50% probability when applied to social phenomena. Studying social phenomena requires an understanding of a huge array of factors that affect human behavior, and any theory of prediction of human behavior is destroyed by the change of any one factor. But perhaps the biggest detractor of Fibonacci theory is that NO causative engine has been or can be determined, a major weakness.
In the future I recommend that you stay quiet and let people think you are ignorant and uninformed, rather than post something that removes all doubt.
You constantly revert to the basher's default -- people who offer different posituions work for the company as paid pumpers. You are pathetic! Try coming up with some FACTS to support your claims and perhaps your credible would be at least equal to CNN's.
The deletions are a sign that a coward who fears opposition is the moderator. FACTS are not tools of a pumper.
The chart says NOTHING. Charts are interpreted. You interpret negatively. You are a serial basher. If people will look at the other boards on which you post, they will see you are consistently negative. Are you a short seller? You seem to have ulterior motives.
The weekly chart has been getting more positive. It is known that there will be a national launch of the new product line 4/15. There may be a revenue announcement around that time as well. The fundamentals will most likely push the stock price higher in the coming weeks, perhaps to a new 52 week high.
I understand. Glad you did it. He takes down my posts because he doesn't like to be made to look foolish. Nevertheless, I am a bit concerned by the selloff after the sharp rise. Though the selloff occurred with much less volume, it may indicate that there is some willingness to sell by flippers who bought around $.50 when they get a 10% to 15% gain. It may be that the flippers are out and we have shares in stronger hands so the next upleg will be more forceful, or it ma be that we need one more surge to move out the flippers. Buyers now are buying on the fundamentals of the company, especially the new product line which will launch national any day. IMO people will hold until they see the efficacy of the marketing program, so the smoothed path will be upward.
We need to resist gloating about this price increase this morning. The volume is slight. However, the tight float and great capital structure accounts for such a move even with small volume. They are two of the fundamental factors that make IMMD attractive.
A dialogue with the serial basher Suvarov is fruitless. He is a negative stock basher with an agenda. Check out the other board on which he posts --SRSR. All his posts are negative. When someone has an agenda you cannot reason with them. His silly justification about "what the charts say" is ridiculous. The charts say nothing. Charts are interpreted. IMMD is still in a crossroads situation. There really is no indication od the next leg at this time. It will be resolved shortly. The most likely source of the resolution will be additional info regarding fundamentals.
Let's see what IMMD possesses. 1) proven efficacious products 2) a superb balance sheet and capital structure 3) Tiny float 4) Upcoming launch of a new product line with credible efficacy and a huge market 5) Strong internal marketing and customer service groups 6) Top shelf medical and scientific Board and Advisory Groups. Buying now is supportable.
Sticking above $.50. This is significant. Look at L2. Not much for sale. Relatively small uptick in demand shoots this to $.80. What could hurt is a disappointment in Q1 rev and profits, but with all the balls in the IMMD airspace it is a risk worth accepting.
Taking down my posts because you do not want opposition? Cowardly! People who brag about their investment prowess are fools covering up their lack of achievement. Charts are mainly useful for points of entry and exit, and even then have a limited usefulness. Though they show trends, fundamental can always foil the chart. With all of the oportunities that IMMD is pursuing, anyone who predicts based on charts is in a minefield of his own making.
Right now the weekly chart is neither bullish nor bearish. The next few days will paint a clearer chart. The BIG thing is the launch of the new line in conjunction with what seems to be a very potent marketing and customer service capability. Those are L-T fundamentals which trump your cracked crystal ball.
People who live and die by the charts usually DIE by the charts. Fundamentals are causative. Charts are a visible representation of pressures. Pressures change with the fundamentals.
While I use charts, they should never be the primary tool. This stock rose not due to charts, but to fundamentals. There has been no new news, so after such a rapid surge it settles back. There will be new info coming soon -- probably a revenue announcement, Q1 financials, maybe new product developments, new research results, geographic expansion into Asia, etc. These will drive IMMD to new highs in the not too distant future.
You are probably correct. There is very little available on L2 up to $.80. Some settling is to be expected. IMO IMMD needs an awareness effort right now to bring more interest from new investors, or perhaps an announcement soon regarding Q1 revenues to resume the climb over $1.00.
No. The board and advisory board consists mostly of MD's, a couple of whom have Ph.D's also. They are people at the top of their fields. The chair is Dr. Bruzzesse. His contact info is on IMMD's website and I expect he may be happy to answer ??
Don't tell me that I am pitching. I am posting facts. You on the other hand are posting unreasonable concerns. I have 10 years' experience with beta glucan with excellent results. You have no experience with IMMD's products. Further, you are making fruit salad here. The hair loss product is not a beta glucan product, but an all natural array of elements that have been beneficial in hair loss. You are probably an anxious person, who needs to calm down and look at facts. Only facts, not your mind at the movies hysterics. First, the topical ointments I listed before have been used for decades with no problems. Second, thalidomide was 60 years ago and the bureaucracy has expanded exponentially since then. Third, this preparation is not a pharmaceutical. It is all natural ingredients that have not been found to be toxic, i.e. they are deemed not to have major health concerns by the FDA, so they do not regulate them.
This is an arena for germane facts. If you have an opinion not based on fact, then state it as your opinion which has no factual basis and move on.
Ditto. I think those concerned with debt or no debt miss the message. As the revenues grow and margins expand, working capital will be available internally for market expansion. Further, Management knows what IMMD has and regional geographic expansion can most likely pursued through JV and licensing arrangements that may include upfront payment to IMMD. Accessing capital is not an issue. The primary issue is extending interest in the products. As shareholders we can help by using the products. I do not need the hair loss remedy, but I have been using the capsules for 10 years and have previously posted about my excellent results and those results of people I know. IMMD's beta glucan works NO DOUBT. Even my doc, who is of the archaic view has told me that my test results are outstanding and my "immune system is extraordinarily strong". That is the goal for promoting health.
While the product may invade the scalp, it is a far-fetched fantasy that it could invade the skull and access the brain. For instance, many topical ointments contain cortisone, mentholatum and other remedies. While they permeate the skin, the FDA has no concerns about them invading the bloodstream or skeleton. relax. Try the product and perhaps you will benefit both in appearance and confidence.
The chart is superlative. If immd breaks through $.80 the next level is $1.20.
The chart is superlative. If immd breaks through $.80 the next level is $1.20.
the immd chart seems unstoppable. clear to $.80
If you can see level 2, it seems to show that the pressure is to the upside. Very little available until the s/p gets to $.70.
IMMD wound tight as a Timex. Very little for sale at this level. Any new interest will send IMMD to .70+++.
Holders of IMMD are only reluctantly parting with shares. Not many shares available below $.70. Next resistance is $.65. Wit any new eyeballs brought to IMMD or any substantive announcement, that resistance will give way and we could easily see $.70 +
Ditto!!!!
The recent Financial article (that was not paid) will bring more eyeballs next week after small cap investors scan and research this weekend. The float is so tight. The selling is over. Any reasonable increase in interest will cause the surge to resume.
My last post has a missing phrase. In the last sentence i left out "this year, then a run rate of $20mm in revenue for the first half of next year"
It is hard to predict s-t movements. This could have continued to run, dropped back a little and roared beyond.95, or hugged a straight line. Look at predictable medium term trends. I started buying this stock 10 years ago at $.05. I had opportunities to sell over the years at $.40. Never did. I continuously reviewed their research and discussed it with Doc friends of mine. I am a user for 10 years and in that time I have gotten only 2 very minor colds. No flu, no viruses, etc. At my last physical my Doc told me "Your immune system is extremely strong." (As measured by blood work related to inflammation, etc.) I have numerous examples of extraordinary reversals of disease in people I know. The missing element has been marketing, customer retention, internet sales. They have that now and 2 more product lines and perhaps another coming on stream.
In 18 months, I predict $2.00/share. For that to occur they need 10 - 12 million in revenues, 10% pretax and a P/E of 20 (which in this industry and with such rapid growth is reasonable.)
I believe before May 15th. They may have a revenue announcement as early as April 15th.
Hindsight is not relevant.
This article states what I have been posting in a more convincing manner:
ImmuDyne Inc (OTCMKTS:IMMD) is up nearly 200% month to date, and is coming off the back of a few major early 2017 catalysts. This is a company that has basically sat in and around the same price for twelve months or more. The company’s rocketing from $0.25 to its current $0.8, for us, hints at a fundamental sentiment shift, and one that – in turn – suggests there’s some longer term growth potential here.So, with that as a base, here’s a look at the business update and what we want to see going forward as supportive of our longer term bull thesis.
Immudyne is a healthcare stock based out of New York that has developed a range of products rooted in a scientific compound called a beta glucan. These are naturally occurring polysaccharides that are found in the cell walls of cereals, yeast, bacteria, and fungi, and there’s a wealth of data to suggest that they have various health benefits for humans, when formulated in certain ways.
We’re not going to go into the science, or the data that supports its validity, in too much detail here. Sure, that the products work as advertised is important, but we’re not looking at FDA regulated drugs or anything like that. These are OTC health and wellness products. In our eyes, it’s more about marketing than it is about data – something we’ll come back to shortly.
So what did the latest business update tell us?
Well, the company had a pretty solid 2016. It’s share price across the period doesn’t really reflect this, but the milestones do. Specifically, the company was able to scale its direct to consumer skincare line from nothing to over $4.0M in top-line revenue. Just as importantly, it managed to do so with very little dilution to shareholders – circa $500k in outside investment raised at $0.23 per share. Management also reported the development of a superior formulation for its OTC line, and the signing of a couple of new endorsement deals, one of which saw it in-license a patented hair loss shampoo and conditioner from two guys –Dr. Steven Shapiro and Dr. Michael Borenstein – who are reportedly opinion leading dermatologists in Florida. The company also commissioned a study that demonstrated that its core ingredient, the above mentioned beta glucans, have a positive effect on Langerhans cell (these are the dendritic cells of the skin) activity, as well as protecting skin from UV rays and pollutants. As we said, this latter data collection is really only important for us in terms of how the data transfers to a sound byte for marketing, and in this case, it transfers pretty well.
Anyway, that’s last year. What we’re really interested in is the company’s taking over of its own marketing platform. Its in-house team, called ImmuDyne PR, which reportedly includes 10 employees and a call center operation, is (as per management’s latest communication) going to reduce customer acquisition costs by nearly 50% from 2016 levels. We’ve said it twice already, and we’ll say it again – this company is now all about marketing. It’s got a solid product base and it’s got a fresh range about to launch, and value over the coming twelve months is going to be dictated by how effectively the company can put the cash it’s got to use in acquiring customers. Management seems to understand this, and has proven it can allocate efficiently already (and the in-house team should improve further on this efficiently).
Looking at the numbers, the company was able to grow top line from $714K to $1.25 million between 2014 and 2015, and expects to report full year 2016 at $5 million. 2017 estimates put revenues at nearly $10 million. For reference, and even taking the latest run into consideration, the market currently values this company at just $27 million.Disclosure:
We have no position in IMMD and have not been compensated for this article.
Your statement assumes that you will select another investment that wil go uip at a rate that would exceed the next move for IMMD. One can make the argument that the information contained in the Business Outlook, including the addition of well-developed marketing and customer support groups that are already proving to be effective, the launch of the hair loss line and the study under way for new uses for their beta glucan product, presents an extraordinary opportunity for a superlative gain, that would be hard to match. BUY ON ANY PULLBACKS.
The weekly chart still says $1.20 despite small pullback today, which is to be expected.
Near term $1.20. Look at the charts. New hair loss product line. Very low float (60% held by insiders). Rapid sales increase will be reported for Q1. Earnings going positive also.
ImmuDyne Provides 2017 Business Outlook Globe Newswire 9:05 am ET 3/6/17.
Check out this very welcome announcement.
IMMD now has a credible plan of operation with ALL the elements in place. IMMD has 3 world-class product lines, a real and effective marketing organization in place that is now showing results, an internally managed customer relations and retention program that is already adding to profitability, a pristine balance sheet that will protect shareholders from any significant dilution, an augmented management team and now some ongoing research to uncover more uses for its beta glucan product.
IMMD may be one of the 5 best small caps in this space right now, maybe one of the 3 best due to its tight capital structure and miniscule float. I am so glad I held on to my shares during the quiet years. IMMD is ready to pop and ready for the long term.
IMO there are announcements on the way. This much volume and this much money suggests that something big is developing.
Another add on to the last week of trading. We will trade over 1 million shares ($400,000) and rise 35% today. Next week this should continue. In the last 2 days dollar value of trading has been $525,000. This would seem to be hedge fund money. I am somewhat surprised with the short time span of the accumulation which has pushed up the price so rapidly. That may mean that this group sees extraordinary upside and that we can rely on them holding for that major pot of gold in the future. They are probably not short-term flippers.
Great action and close today at near the top of the range. Almost 400,000 share volume and $125,00) cash. Looks like there is a lot of interest by perhaps fund(s).
The action today, on top of the gradual increase of the last week, sets up the IMMD chart to exceed last year's high of $.39. Watch dor IMMD to blow past $.40. IMO the recent announcements are getting attention from new investors. This is exactly what this company has needed -- fresh money. Based on similar nutriceutical firms with similar financial set up, but with a far less attractive balance sheet and capital structure, IMMD should be valued at $.55 to $.60 per share. Hold on for the ride. Further, enhancement will occur if we get good first Q financials and a growing run rate into 2Q, or perhaps a new product development or entry into Asia.
Check out the latest Corporate Presentation announced by the filing of a new 8K today. It is very impressive. I can tell the management team has been diligently pursuing several relevant and promising marketing opportunities. A review of the entire presentation leaves the reader with the strong feeling that IMMD is a substantial company, destined to be a real player in the global alternative medical field.
If there is wrong doing on Keevil's part and The Board has PROOF, they can pressure Keevil to voluntarily return some or all of his shares or suffer the consequences of possible criminal action. Further, the Keevil family may be a source of additional pressure on Keevil to "do the right thing", as they will certainly want to avoid a scandal that could besmirch the family name.